FibroBiologics (FBLG) Competitors

$11.80
+0.31 (+2.70%)
(As of 05/16/2024 ET)

FBLG vs. AMRN, RVNC, ORGO, ANRO, ACIU, TERN, NBTX, PGEN, KRRO, and VRCA

Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Amarin (AMRN), Revance Therapeutics (RVNC), Organogenesis (ORGO), Alto Neuroscience (ANRO), AC Immune (ACIU), Terns Pharmaceuticals (TERN), Nanobiotix (NBTX), Precigen (PGEN), Korro Bio (KRRO), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical preparations" industry.

FibroBiologics vs.

FibroBiologics (NASDAQ:FBLG) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment.

Amarin received 842 more outperform votes than FibroBiologics when rated by MarketBeat users.

CompanyUnderperformOutperform
FibroBiologicsN/AN/A
AmarinOutperform Votes
842
74.45%
Underperform Votes
289
25.55%

FibroBiologics has higher earnings, but lower revenue than Amarin.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
FibroBiologicsN/AN/A-$16.49MN/AN/A
Amarin$277.46M1.35-$59.11M-$0.12-7.60

22.3% of Amarin shares are owned by institutional investors. 2.0% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

FibroBiologics has a net margin of 0.00% compared to Amarin's net margin of -18.96%. FibroBiologics' return on equity of 0.00% beat Amarin's return on equity.

Company Net Margins Return on Equity Return on Assets
FibroBiologicsN/A N/A N/A
Amarin -18.96%-9.48%-6.34%

In the previous week, FibroBiologics had 5 more articles in the media than Amarin. MarketBeat recorded 6 mentions for FibroBiologics and 1 mentions for Amarin. Amarin's average media sentiment score of 1.37 beat FibroBiologics' score of 0.54 indicating that Amarin is being referred to more favorably in the news media.

Company Overall Sentiment
FibroBiologics Positive
Amarin Positive

Amarin has a consensus target price of $1.08, indicating a potential upside of 18.73%. Given Amarin's higher probable upside, analysts clearly believe Amarin is more favorable than FibroBiologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FibroBiologics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Amarin
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75

Summary

Amarin beats FibroBiologics on 7 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FBLG vs. The Competition

MetricFibroBiologicsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$385.03M$6.72B$5.11B$7.96B
Dividend YieldN/A2.74%37.02%3.93%
P/E RatioN/A23.26170.5718.78
Price / SalesN/A256.912,310.3479.10
Price / CashN/A35.2336.0031.19
Price / Book295.006.405.464.47
Net Income-$16.49M$138.38M$105.07M$217.14M
7 Day Performance35.01%0.23%1.66%1.89%
1 Month Performance7.37%2.49%3.87%5.33%
1 Year PerformanceN/A0.63%7.88%11.56%

FibroBiologics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMRN
Amarin
0.3827 of 5 stars
$0.91
-1.1%
$1.08
+19.1%
-28.0%$373.63M$306.91M-7.58275Gap Up
RVNC
Revance Therapeutics
4.294 of 5 stars
$3.48
+4.8%
$11.50
+230.5%
-90.2%$363.49M$234.04M-0.96597Analyst Forecast
High Trading Volume
ORGO
Organogenesis
4.0412 of 5 stars
$2.85
-3.7%
$4.83
+69.9%
-6.6%$377.17M$435.47M71.14862Earnings Report
ANRO
Alto Neuroscience
2.3258 of 5 stars
$14.18
+0.6%
$32.33
+128.1%
N/A$381.08M$210,000.000.00N/AAnalyst Forecast
News Coverage
ACIU
AC Immune
2.4897 of 5 stars
$3.58
+8.5%
$16.00
+346.9%
+67.1%$354.06M$16.48M-5.04133Analyst Revision
News Coverage
High Trading Volume
TERN
Terns Pharmaceuticals
3.6395 of 5 stars
$5.99
+1.7%
$14.94
+149.4%
-49.5%$387.43M$1M-4.7266Analyst Forecast
Analyst Revision
News Coverage
NBTX
Nanobiotix
1.8538 of 5 stars
$7.29
+6.4%
$11.00
+50.9%
+55.9%$343.58M$39.18M0.00101Positive News
Gap Up
PGEN
Precigen
4.2726 of 5 stars
$1.37
+1.5%
$10.00
+629.9%
+19.0%$341.02M$6.22M-3.51202Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
KRRO
Korro Bio
2.8631 of 5 stars
$50.05
-0.4%
$126.25
+152.2%
N/A$401.55M$14.07M-0.53101Analyst Forecast
Short Interest ↓
News Coverage
VRCA
Verrica Pharmaceuticals
4.1031 of 5 stars
$9.49
-0.7%
$11.25
+18.5%
+49.2%$402.57M$5.12M-6.50100Analyst Forecast
News Coverage
High Trading Volume

Related Companies and Tools

This page (NASDAQ:FBLG) was last updated on 5/16/2024 by MarketBeat.com Staff

From Our Partners